Skip to main content
. 2022 Nov 2;57(Suppl 1):100–416. doi: 10.1038/s41409-022-01798-0
Adults with allo-HSCT (n = 296) Pediatrics with allo-HSCT (n = 21) Adults at risk (n = 250) Pediatrics at risk (n = 19)
no GvHD 107 (36.1%) 15 (71.4%) 70 (28.0%) 13 (68.4%)
aGvHD 127 (42.9%) 6 (28.6%) 118 (47.2%) 6 (31.6%)
laGvHD 28 (9.5%) 1 (4.8%) 28 (11.2%) 1 (5.3%)
cGvHD 109 (37.2%) 2 (9.5%) 109 (43.6%) 2 (10.5%)
mild 56 (51.4%) 0 (0.0%) 56 (51.4%) 0 (0.0%)
moderate 43 (38.5%) 1 (50.0%) 43 (38.5%) 1 (50.0%)
severe 10 (8.3%) 1 (50.0%) 10 (8.3%) 1 (50.0%)